Winrevair

News

NICE backs stomach cancer, PAH drugs for NHS use

AZ's Imfinzi is the first NHS immunotherapy for a form of stomach cancer, while MSD's Winrevair gets a green light for rare respiratory disease PAH.

News

MSD trims outlook as it aims to shave $3bn off costs

MSD is embarking on a $3bn cost-reduction drive to prepare for the loss of patent protection for cancer blockbuster Keytruda.

News

MSD adds rocket fuel to Winrevair's engine in PAH

ZENITH trial of MSD's Winrevair in PAH could add further momentum to an already impressive launch

News

MSD leaps on FDA approval of PAH drug sotatercept

MSD’s sotatercept has become the first FDA-approved therapy for pulmonary arterial hypertension (PAH) that addresses the underlying mechanism behind the disease, rather th

NICE backs stomach cancer, PAH drugs for NHS use

MSD trims outlook as it aims to shave $3bn off costs

MSD adds rocket fuel to Winrevair's engine in PAH

MSD leaps on FDA approval of PAH drug sotatercept

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

Winrevair

Editor's Picks